Login / Signup

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Tarun MehraJudith E LupatschThibaud KösslerKonstantin DedesAlexander Reinhard SiebenhünerRoger von MoosAndreas WickiMatthias E Schwenkglenks
Published in: PloS one (2024)
Olaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • dna repair
  • emergency department
  • oxidative stress
  • dna damage
  • drug induced
  • smoking cessation